Scotiabank cuts SNDX stock target, keeps rating on FDA approval risk
SNDX Stock | USD 15.57 0.33 2.17% |
Slightly above 58% of all Syndax Pharmaceuticals' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Syndax Pharmaceuticals suggests that some traders are interested. Syndax Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Syndax Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Syndax |
Scotiabank cuts SNDX stock target, keeps rating on FDA approval risk
Read at investing.com
![]() |
Syndax Pharmaceuticals Current Investor Sentiment
Comfort Level 58
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Syndax Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Syndax Pharmaceuticals.
News SentimentNeutral | Hype SentimentBullish | Insider SentimentWaiting |
Syndax Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Syndax Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Syndax Pharmaceuticals Historical Investor Sentiment
Investor biases related to Syndax Pharmaceuticals' public news can be used to forecast risks associated with an investment in Syndax. The trend in average sentiment can be used to explain how an investor holding Syndax can time the market purely based on public headlines and social activities around Syndax Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Syndax Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Syndax Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Syndax Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Syndax Pharmaceuticals.
Syndax Pharmaceuticals Maximum Pain Price Across April 17th 2025 Option Contracts
Syndax Pharmaceuticals' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Syndax Pharmaceuticals close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Syndax Pharmaceuticals' options.
Syndax Pharmaceuticals Fundamental Analysis
We analyze Syndax Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syndax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syndax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Syndax Pharmaceuticals is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Syndax Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Syndax Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Syndax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Syndax Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Syndax Pharmaceuticals Related Equities
KALV | Kalvista Pharmaceuticals | 5.70 | ||||
MLYS | Mineralys Therapeutics, | 4.65 | ||||
DYN | Dyne Therapeutics | 3.24 | ||||
MRSN | Mersana Therapeutics | 3.08 | ||||
MRUS | Merus BV | 1.98 | ||||
EWTX | Edgewise Therapeutics | 1.95 | ||||
CYTK | Cytokinetics | 1.59 | ||||
AVTE | Aerovate Therapeutics | 0.83 | ||||
VRDN | Viridian Therapeutics | 0.39 | ||||
PLRX | Pliant Therapeutics | 0.32 | ||||
PCVX | Vaxcyte | 0.24 | ||||
KROS | Keros Therapeutics | 0.09 | ||||
LRMR | Larimar Therapeutics | 0.68 | ||||
CGEM | Cullinan Oncology | 1.29 | ||||
REPL | Replimune | 1.85 | ||||
RVMD | Revolution Medicines | 2.03 | ||||
STRO | Sutro Biopharma | 2.42 | ||||
INZY | Inozyme Pharma | 2.42 | ||||
COGT | Cogent Biosciences | 3.43 |
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.